Amarin Corporation plc
AMRN
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $281.9M
$13.63
▼ -0.58%
P/E
-14.22
Mkt Cap
$281.9M
52-Wk Range
$12.96–$20.90
52-Week Range
$12.96 - $20.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 7.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- FDA-approved lead product with established clinical efficacy in reducing triglycerides
- Strong intellectual property portfolio protecting core therapeutic formulations
- Established distribution network through wholesalers and specialty pharmacies
- Strategic partnerships with global pharmaceutical companies like Mochida Pharmaceutical
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Expanding VASCEPA prescriptions and market penetration in the United States
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-4.0% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AMRN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of -$0.02 vs -$0.01 consensus (-100.0% surprise). Revenue of $42.2M vs $44.5M expected (-5.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-100.0%
Revenue trend · last 8Q
—
—
—
+8%
+17%
-21%
+3%
-46%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$42.3M
$62.3M
$42.0M
$72.7M
$49.7M
$49.1M
$43.3M
$39.1M
Margins · last 8Q
Gross
38.4%
Operating
-30.6%
Profit
-19.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AMRN stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related